The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 17, 2016
Filed:
Dec. 06, 2013
Vertex Pharmaceuticals Incorporated, Cambridge, MA (US);
Nadia Ahmad, Didcot, GB;
Dean Boyall, Faringdon, GB;
Jean-Damien Charrier, Grove, GB;
Chris Davis, Salisbury, GB;
Rebecca Davis, Witney, GB;
Steven Durrant, Abingdon, GB;
Gorka Etxebarria I Jardi, Abingdon, GB;
Damien Fraysse, Abingdon, GB;
Juan-Miguel Jimenez, Abingdon, GB;
David Kay, Purton, GB;
Ronald Knegtel, Abingdon, GB;
Donald Middleton, Sandwich, GB;
Michael O'Donnell, Abingdon, GB;
Maninder Panesar, Didcot, GB;
Francoise Pierard, Abingdon, GB;
Joanne Pinder, Didcot, GB;
David Shaw, Oxford, GB;
Pierre-Henri Storck, Abingdon, GB;
John Studley, Witney, GB;
Heather Twin, Wantage, GB;
Vertex Pharmaceuticals Incorporated, Boston, MA (US);
Abstract
The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.